On July 31, the website of the Chinese medicine network was listed as the main board of the Shanghai stock exchange, which is referred to as "dashen Lin", and the securities code was 603233.
As of the close of 31, the company's share price was 35.60 yuan, up 44.01 percent from its ipo price of 24.72 yuan and its total market value reached 14.24 billion yuan. First-day gain 44% lock, as after landing a-share three pharmaceutical retail enterprises listed on the first day of sight (formerly one hall, common people, yi feng pharmacies offer price is 12.20 yuan, 16.41 yuan and 19.47 yuan respectively).
The company issued 4.001 million shares and raised 989 million yuan, with a price-to-earnings ratio of 22.99 times and a new share price of 24.72 yuan per share. Its share offering price and raise amount have set the highest record of domestic listed pharmacy. The personage inside course of study estimates, combining the new listings after at least 5 ~ 8 harden board (excluding) on the first day, big and Lin's share price of 57.33 yuan or more, extrapolating to the total market value or will race to 22 billion yuan of above.
According to the big and Lin prospectus publicly raised fund use plan, start is still in the pharmaceutical chain marketing network construction project, is expected to invest more than 9, new stores more than 1300 in three years. The "enclosure" speed of the three listed drugstores, from last year's single-minded, yifeng pharmacy and the people's pharmacy, has been remarkably effective.
Drugstore chain rate or continue to pull up
The data shows that the drug retail market has bottomed out and the rate of linkage has accelerated in the past two years.
In 2016, according to the statistical analysis of medicine circulation industry operation report disclosure of data, in 2016, represented by the listed company of the large retail chain enterprises merger and acquisition (m&a) speed, rate of retail chain continued ascension. By November 2016, the retail chain had reached 49.4%, up 3.7 percentage points from the previous year. Data show that the market share of national leading enterprises increased slightly from the previous year, while the market share of regional retail chains declined slightly. This further reflects the trend of market sales gradually to large chain enterprises.
And from the point of rolling year sales growth, domestic retail market growth in the third quarter of 2016 stage after bottoming out rapidly stabilized, gradually warming at the end of 2016, the first quarter of 2017 has bounced back to nearly two and a half high. Predictably, 2016 is likely to be the most difficult period for the Chinese drug retail industry in recent years, and the toughest time in the industry's "harsh winter" has survived. It is not difficult to speculate that the large retail pharmacies that have been listed in the future will continue to increase the level of horizontal mergers and acquisitions, further expand the scale of operation and coverage, and consolidate the market lead.
In 2016, the revenue and net profit of the four drugstores
